PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-43.54%
Both companies show declining cash positions (-43.54% vs AVXL's -94.01%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Below half of AVXL's -94.01%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
0.5-0.75x AVXL's -82.51%. Martin Whitman might see risk if this hampers near-term financial flexibility.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
0.5-0.75x AVXL's -82.22%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-14.50%
Less than half of AVXL's -100.00%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.61%
1.1-1.25x AVXL's 8.12%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
6.57%
Less than half of AVXL's -26.20%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Less than half of AVXL's -26.20%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
7.49%
1.1-1.25x AVXL's 6.77%. Bill Ackman questions if the firm is incurring more total obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.05%
0.5-0.75x AVXL's -5.61%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
0.5-0.75x AVXL's -16.20%. Martin Whitman is wary of lagging equity growth vs. competitor.
-43.54%
0.5-0.75x AVXL's -82.22%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
6.57%
Above 1.5x AVXL's 1.83%. Michael Burry sees a major jump. Investigate leverage rationale.
8.17%
Less than half of AVXL's 17.44%. David Dodd sees better deleveraging or stronger cash buildup than competitor.